Annotation Detail
Information
- Associated Genes
- GABRG2
- Associated Variants
-
GABRA1 c.*470A>G
(
ENST00000393943.10,
ENST00000428797.7,
ENST00000437025.6,
ENST00000636573.1,
ENST00000638112.1,
ENST00000638159.1 )
GABRG2 p.Asn196= (p.N196=) ( ENST00000361925.9, ENST00000414552.6, ENST00000638552.1, ENST00000638660.1, ENST00000638772.1, ENST00000639046.1, ENST00000639111.2, ENST00000639213.2, ENST00000639384.1, ENST00000639683.1, ENST00000639975.1, ENST00000640574.1, ENST00000640985.1, ENST00000641017.1 )
GABRA1 c.*470A>G ( ENST00000393943.10, ENST00000428797.7, ENST00000437025.6, ENST00000636573.1, ENST00000638112.1, ENST00000638159.1 )
GABRG2 p.Asn196= (p.N196=) ( ENST00000361925.9, ENST00000414552.6, ENST00000638552.1, ENST00000638660.1, ENST00000638772.1, ENST00000639046.1, ENST00000639111.2, ENST00000639213.2, ENST00000639384.1, ENST00000639683.1, ENST00000639975.1, ENST00000640574.1, ENST00000640985.1, ENST00000641017.1 ) - Associated Disease
- hepatic encephalopathy
- Source Database
- DisGeNET
- Description
- Multivariate analysis indicated that hypoalbuminemia (<3 g/dL), long-acting (t 1/2 > 12-h), high-dosage (>1.5 defined daily dose equivalents) and long-duration (>2-months) BZD use, carrier of variant genotypes (AG + GG) of GABRA 1 (rs2290732) and having the wild genotype (TT) of GABRG 2 (rs211037) were significant predictors of the development of BZD-associated HE in cirrhotic patients.
- Pubmed
- 24482035
- Original source reporting the Gene Disease association
- BeFree
- DisGENET score for the Gene Disease association
- 0.20027144187208
- Year of publication
- 2013
Drugs